Rahul S Desikan1, Wesley K Thompson2, Dominic Holland3, Christopher P Hess4, James B Brewer5, Henrik Zetterberg6, Kaj Blennow7, Ole A Andreassen8, Linda K McEvoy1, Bradley T Hyman9, Anders M Dale10. 1. Department of Radiology, University of California, San Diego, La Jolla. 2. Department of Psychiatry, University of California, San Diego, La Jolla. 3. Department of Neurosciences, University of California, San Diego, La Jolla. 4. Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco. 5. Department of Radiology, University of California, San Diego, La Jolla3Department of Neurosciences, University of California, San Diego, La Jolla. 6. Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at Göteburg University, Mölndal, Gotheburg, Sweden6University College London Institute of Neurology, Queen Square, London, England. 7. Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at Göteburg University, Mölndal, Gotheburg, Sweden. 8. Department of Psychiatry, University of California, San Diego, La Jolla7Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. 9. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. 10. Department of Radiology, University of California, San Diego, La Jolla2Department of Psychiatry, University of California, San Diego, La Jolla.
Abstract
IMPORTANCE: Converging evidence indicates that clusterin, a chaperone glycoprotein, influences Alzheimer disease neurodegeneration. However, the precise role of clusterin in Alzheimer disease pathogenesis is still not well understood. OBJECTIVE: To elucidate the relationship between clusterin, amyloid-β (Aβ), phosphorylated tau (p-tau), and the rate of brain atrophy over time among nondemented older individuals. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort included cognitively normal older participants and individuals with mild cognitive impairment assessed with baseline lumbar puncture and longitudinal structural magnetic resonance imaging. We examined 241 nondemented older individuals from research centers across the United States and Canada (91 participants with a Clinical Dementia Rating score of 0 and 150 individuals with a Clinical Dementia Rating score of 0.5). MAIN OUTCOMES AND MEASURES: Using linear mixed-effects models, we investigated interactions between cerebrospinal fluid (CSF) clusterin, CSF Aβ1-42, and CSF p-tau at threonine 181 (p-tau181p) on the atrophy rate of the entorhinal cortex and hippocampus. RESULTS: Across all participants, we found a significant interaction between CSF clusterin and CSF Aβ1-42 on the entorhinal cortex atrophy rate but not on the hippocampal atrophy rate. Cerebrospinal fluid clusterin was associated with the entorhinal cortex atrophy rate among CSF Aβ1-42-positive individuals but not among CSF Aβ1-42-negative individuals. In secondary analyses, we found significant interactions between CSF Aβ1-42 and CSF clusterin, as well as CSF Aβ1-42 and CSF p-tau181p, on the entorhinal cortex atrophy rate. We found similar results in subgroup analyses within the mild cognitive impairment and cognitively normal cohorts. CONCLUSIONS AND RELEVANCE: In nondemented older individuals, Aβ-associated volume loss occurs in the presence of elevated clusterin. The effect of clusterin on Aβ-associated brain atrophy is not confounded or explained by p-tau. These findings implicate a potentially important role for clusterin in the earliest stages of the Alzheimer disease neurodegenerative process and suggest independent effects of clusterin and p-tau on Aβ-associated volume loss.
IMPORTANCE: Converging evidence indicates that clusterin, a chaperone glycoprotein, influences Alzheimer disease neurodegeneration. However, the precise role of clusterin in Alzheimer disease pathogenesis is still not well understood. OBJECTIVE: To elucidate the relationship between clusterin, amyloid-β (Aβ), phosphorylated tau (p-tau), and the rate of brain atrophy over time among nondemented older individuals. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort included cognitively normal older participants and individuals with mild cognitive impairment assessed with baseline lumbar puncture and longitudinal structural magnetic resonance imaging. We examined 241 nondemented older individuals from research centers across the United States and Canada (91 participants with a Clinical Dementia Rating score of 0 and 150 individuals with a Clinical Dementia Rating score of 0.5). MAIN OUTCOMES AND MEASURES: Using linear mixed-effects models, we investigated interactions between cerebrospinal fluid (CSF) clusterin, CSF Aβ1-42, and CSF p-tau at threonine 181 (p-tau181p) on the atrophy rate of the entorhinal cortex and hippocampus. RESULTS: Across all participants, we found a significant interaction between CSF clusterin and CSF Aβ1-42 on the entorhinal cortex atrophy rate but not on the hippocampal atrophy rate. Cerebrospinal fluid clusterin was associated with the entorhinal cortex atrophy rate among CSF Aβ1-42-positive individuals but not among CSF Aβ1-42-negative individuals. In secondary analyses, we found significant interactions between CSF Aβ1-42 and CSF clusterin, as well as CSF Aβ1-42 and CSF p-tau181p, on the entorhinal cortex atrophy rate. We found similar results in subgroup analyses within the mild cognitive impairment and cognitively normal cohorts. CONCLUSIONS AND RELEVANCE: In nondemented older individuals, Aβ-associated volume loss occurs in the presence of elevated clusterin. The effect of clusterin on Aβ-associated brain atrophy is not confounded or explained by p-tau. These findings implicate a potentially important role for clusterin in the earliest stages of the Alzheimer disease neurodegenerative process and suggest independent effects of clusterin and p-tau on Aβ-associated volume loss.
Authors: Rahul S Desikan; Linda K McEvoy; Wesley K Thompson; Dominic Holland; J Cooper Roddey; Kaj Blennow; Paul S Aisen; James B Brewer; Bradley T Hyman; Anders M Dale Journal: Ann Neurol Date: 2011-10-14 Impact factor: 10.422
Authors: Rahul S Desikan; Florent Ségonne; Bruce Fischl; Brian T Quinn; Bradford C Dickerson; Deborah Blacker; Randy L Buckner; Anders M Dale; R Paul Maguire; Bradley T Hyman; Marilyn S Albert; Ronald J Killiany Journal: Neuroimage Date: 2006-03-10 Impact factor: 6.556
Authors: Madhav Thambisetty; Yang An; Anna Kinsey; Deepthi Koka; Muzamil Saleem; Andreas Güntert; Michael Kraut; Luigi Ferrucci; Christos Davatzikos; Simon Lovestone; Susan M Resnick Journal: Neuroimage Date: 2011-07-28 Impact factor: 6.556
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Christine Fennema-Notestine; Donald J Hagler; Linda K McEvoy; Adam S Fleisher; Elaine H Wu; David S Karow; Anders M Dale Journal: Hum Brain Mapp Date: 2009-10 Impact factor: 5.038
Authors: Stefanie H Freeman; Ruth Kandel; Luis Cruz; Anete Rozkalne; Kathy Newell; Matthew P Frosch; E Tessa Hedley-Whyte; Joseph J Locascio; Lewis A Lipsitz; Bradley T Hyman Journal: J Neuropathol Exp Neurol Date: 2008-12 Impact factor: 3.685
Authors: Madhav Thambisetty; Andrew Simmons; Latha Velayudhan; Abdul Hye; James Campbell; Yi Zhang; Lars-Olof Wahlund; Eric Westman; Anna Kinsey; Andreas Güntert; Petroula Proitsi; John Powell; Mirsada Causevic; Richard Killick; Katie Lunnon; Steven Lynham; Martin Broadstock; Fahd Choudhry; David R Howlett; Robert J Williams; Sally I Sharp; Cathy Mitchelmore; Catherine Tunnard; Rufina Leung; Catherine Foy; Darragh O'Brien; Gerome Breen; Simon J Furney; Malcolm Ward; Iwona Kloszewska; Patrizia Mecocci; Hilkka Soininen; Magda Tsolaki; Bruno Vellas; Angela Hodges; Declan G M Murphy; Sue Parkins; Jill C Richardson; Susan M Resnick; Luigi Ferrucci; Dean F Wong; Yun Zhou; Sebastian Muehlboeck; Alan Evans; Paul T Francis; Christian Spenger; Simon Lovestone Journal: Arch Gen Psychiatry Date: 2010-07
Authors: Peter Kukumberg; Martin Karlík; Denisa Beňová-Liszeková; Milan Beño; Tibor Pechan; Robert Farkaš Journal: Neuro Endocrinol Lett Date: 2015 Impact factor: 0.765
Authors: Siddhita D Mhatre; Connie A Tsai; Amanda J Rubin; Michelle L James; Katrin I Andreasson Journal: Trends Neurosci Date: 2015-10 Impact factor: 13.837
Authors: Yuetiva Deming; Jian Xia; Yefei Cai; Jenny Lord; Peter Holmans; Sarah Bertelsen; David Holtzman; John C Morris; Kelly Bales; Eve H Pickering; John Kauwe; Alison Goate; Carlos Cruchaga Journal: Neurobiol Aging Date: 2015-09-25 Impact factor: 4.673